Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 10/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.39 |
| ▸ | CDK4 | P11802 | 4/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20203598 | 0.92 | GRM5 (0.47) | HSP90AA1GRM5CDK4CDK1CCNB1 | |
| SCHEMBL20203597 | 0.92 | GRM5 (0.47) | HSP90AA1GRM5CDK4CDK1CCNB1 | |
| SCHEMBL20203457 | 0.91 | GRM5 (0.49) | HSP90AA1GRM5CDK4CDK1CCNB1 | |
| SCHEMBL22876917 | 0.85 | CDK4 (0.39) | HSP90AA1GRM5CDK4CDK1CCNB1 | |
| SCHEMBL23733484 | 0.84 | GRM5 (0.42) | GRM5CDK4CDK1CCNB1CCNE1 | |
| SCHEMBL20203431 | 0.84 | KEAP1 (0.41) | HSP90AA1GRM5HSP90B1CDK4CDK1 | |
| SCHEMBL23733483 | 0.83 | CDK4 (0.35) | HSP90AA1HSP90B1CDK4CDK1GABRG2 | |
| SCHEMBL20203456 | 0.82 | GRM5 (0.41) | HSP90AA1GRM5CDK4CDK1CCNB1 | |
| SCHEMBL20203531 | 0.82 | TLR9 (0.41) | HSP90AA1GRM5HSP90B1CDK4CDK1 | |
| SCHEMBL21414436 | 0.82 | GRM5 (0.44) | HSP90AA1GRM5CDK4CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| WO-2018097297-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | HSP90AA1 4289/4885GRM5 2518/4885HSP90B1 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.